Table 3 Treatment-related adverse events of special interest in apatinib-exposed patients (n = 1999)
Treatment-related adverse events of special interest, n (%) | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | All Gradeb | Grade ≥ 3b |
|---|---|---|---|---|---|---|---|
Any event | 211 (11%) | 527 (26%) | 883 (44%) | 79 (4%) | 57 (3%) | 1485 (74%) | 1019 (51%) |
Hypertensiona | 127 (6%) | 328 (16%) | 520 (26%) | 5 (< 1%) | 0 | 980 (49%) | 525 (26%) |
 Hypertension | 113 (6%) | 300 (15%) | 487 (24%) | 3 (< 1%) | 0 | 903 (45%) | 490 (25%) |
Proteinuriaa | 126 (6%) | 142 (7%) | 61 (3%) | 1 (< 1%) | 0 | 685 (34%) | 89 (4%) |
 Proteinuria | 252 (13%) | 201 (10%) | 76 (4%) | 1 (< 1%) | 0 | 530 (27%) | 77 (4%) |
Hand-foot syndromea | 126 (6%) | 142 (7%) | 61 (3%) | 1 (< 1%) | 0 | 330 (17%) | 62 (3%) |
Overall bleedinga | 338 (17%) | 100 (5%) | 64 (3%) | 12 (1%) | 26 (1%) | 540 (27%) | 102 (5%) |
 Gastrointestinal hemorrhage | 56 (3%) | 49 (2%) | 37 (2%) | 12 (1%) | 23 (1%) | 177 (9%) | 72 (4%) |
 CNS bleeding | 0 | 0 | 0 | 1 (< 1%) | 2 (< 1%) | 3 (< 1%) | 3 (< 1%) |
 Laboratory abnormality | 258 (13%) | 43 (2%) | 12 (1%) | 1 (< 1%) | 0 | 314 (16%) | 13 (1%) |
 Fecal occult blood positive | 238 (12%) | 39 (2%) | 11 (< 1%) | 0 | 0 | 288 (14%) | 11 (< 1%) |
Hepatotoxicitya | 295 (15%) | 155 (8%) | 126 (6%) | 19 (1%) | 5 (< 1%) | 600 (30%) | 150 (8%) |
 Laboratory abnormality | 237 (12%) | 117 (6%) | 97 (5%) | 9 (< 1%) | 0 | 460 (23%) | 106 (5%) |
 Alanine aminotransferase increase | 115 (6%) | 34 (2%) | 20 (1%) | 0 | 0 | 169 (8%) | 20 (1%) |
 Aspartate aminotransferase increase | 179 (9%) | 42 (2%) | 25 (1%) | 1 (< 1%) | 0 | 247 (12%) | 26 (1%) |
 Serum bilirubin increase | 122 (6%) | 59 (3%) | 28 (1%) | 5 (< 1%) | 0 | 214 (11%) | 33 (2%) |
 Hepatobiliary disease | 91 (5%) | 52 (3%) | 36 (2%) | 11 (1%) | 5 (< 1%) | 195 (10%) | 52 (3%) |
 Hepatic injury | 76 (4%) | 43 (2%) | 30 (2%) | 5 (< 1%) | 4 (< 1%) | 158 (8%) | 39 (2%) |
Cardiac toxicity a | 31 (2%) | 9 (1%) | 7 (< 1%) | 0 | 0 | 47 (2%) | 7 (< 1%) |